A phase III study of novel epothilone (ixabepilone) plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and a taxane.

Trial Profile

A phase III study of novel epothilone (ixabepilone) plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and a taxane.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2016

At a glance

  • Drugs Capecitabine; Ixabepilone
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 10 Jul 2010 Results published in JCO.
    • 09 Oct 2008 Checked against ClinicalTrials.gov record. Last updated 9 October 2008.
    • 05 Sep 2008 Primary endpoint 'Overall survival duration' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top